GMOs are blocked now, but the plan is a boon for biotech – that is all of their modeling claims.
CEO 2021 - Corporate Europe Observatory has been tracking the industry’s lobby attempts to get new GM techniques deregulated since 2015 ["Derailing EU rules on new GMOs," Mar 29, https://corporateeurope.org/en/2021/03/derailing-eu-rules-new-gmos]
For many years the biotech industry has lobbied the European Commission not to regulate products made using new GMO techniques, including ‘genome editing’ techniques such as CRISPR-Cas. Sidenote However on 25 July 2018 the European Court of Justice ruled that such genome editing procedures are GM techniques and its products must be regulated as such. Since then, industry and researchers have been pushing hard to change the EU GMO law (2001/18) in order to get genome editing deregulated (ie with no risk assessment, monitoring, or labelling).
But there are two huge hurdles to overcome. First, each decision on GMOs in the EU is highly contested, therefore it will be hard to find enough support to overhaul the EU GMO regulations. Second, and connected to the first, public support also has to be won. Therefore, wild promises are being made about the alleged benefits of crops and animals which are made using genome editing techniques, to convince the public of their value. Similar promises were also made for GMOs in the past, but never proved true.
The lobby tactics described in this briefing appear to firstly focus on legal strategy, and secondly, to develop a positive PR narrative of, for example, climate-friendly ‘flagship products’, in order to gain public acceptance for new GMOs. They are also a good example of the typical echo-chamber that comes with big industry lobby campaigns, whereby decision makers are exposed to multiple voices all bringing the same message. The lobby initiatives described in this briefing appear to be driven by public research organisations, however they have close ties to corporate interests.